Bruker (BRKR) Wolfe Research 2024 Healthcare Conference summary

Recent performance and market dynamics

• Achieved double-digit organic revenue growth over the past three years, outperforming peers and maintaining strong growth even in challenging market conditions.

• Noted softness in China and biopharma markets, with China representing 14% of revenue and biopharma seeing weaker order bookings in recent quarters.

• Industrial, clean tech, and semiconductor segments performed well, with semiconductor revenue benefiting from onshoring trends.

• U.S. revenue accounts for about 25% of the total, with 75% of business ex-U.S., reducing exposure to U.S.-specific risks.

• China stimulus program is expected to drive future growth, with significant RFP activity and provincial funding underway.

Strategic outlook and guidance

• Operating margin expansion has been strong, though recent acquisitions have been dilutive; EPS impact from acquisitions expected to be neutral or accretive by 2026.

• Medium-term outlook remains positive, though the growth path may be less linear due to end market conditions.

• M&A activity has focused on high-growth, strategic areas aligned with Project Accelerate 2.0, with integration progressing well.

• Recent acquisitions, including NanoString, are being integrated into divisions, with positive early results and margin improvement initiatives underway.

• Legal overhangs in Europe have been resolved, allowing unencumbered market access; U.S. legal developments expected in spring 2025.

End market and geographic trends

• Academic and government research markets outside the U.S. remain strong, with U.S. government funding representing a modest portion of total revenue.

• Semiconductor and industrial markets are key growth drivers, supported by global onshoring and clean tech trends.

• China remains a vibrant market, with most revenue delivered through European operations, limiting U.S.-China trade risk.

• Provincial administration of China’s 2024 stimulus program is expected to drive order activity, with timing of revenue recognition dependent on product mix and lead times.

• Portfolio diversity and ongoing innovation position the business for continued growth despite U.S. market choppiness.